

CITATION REPORT

List of articles citing

Lutetium Lu 177 Vipivotide Tetraxetan: First Approval.

DOI: 10.1007/s40291-022-00594-2
Molecular Diagnosis and Therapy, 2022, , 1.

Source: <https://exaly.com/paper-pdf/145469891/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
14	Comparative analysis of cancer cell responses to targeted radionuclide therapy (TRT) and external beam radiotherapy (EBRT). 2022 , 15,		0
13	Novel Salinomycin-Based Paramagnetic Complexes First Evaluation of Their Potential Theranostic Properties. 2022 , 14, 2319		0
12	CD46 targeted ²¹² Pb alpha particle radioimmunotherapy for prostate cancer treatment.		0
11	Advances in ¹⁷⁷ Lu-PSMA and ²²⁵ Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer. 2022 , 14, 2166		2
10	Learn from antibody drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy. 2022 , 11,		1
9	Cure of disseminated human lymphoma with [¹⁷⁷ Lu]Lu-ofatumumab in a preclinical model. jnumed.122.264816		0
8	The past, present, and future of chemotherapy with a focus on individualization of drug dosing. 2022 , 352, 840-860		2
7	FDA-Approved Small Molecules in 2022: Clinical Uses and Their Synthesis. 2022 , 14, 2538		0
6	Development of radiopharmaceuticals for targeted alpha therapy: Where do we stand?. 9,		0
5	Novel PSMA-Targeting Radionuclide Peptidomimetics for Treating Prostate Cancer.		0
4	2022 FDA TIDES (Peptides and Oligonucleotides) Harvest. 2023 , 16, 336		0
3	Radiomics and theranostics with molecular and metabolic probes in prostate cancer: toward a personalized approach. 2023 , 23, 243-255		0
2	A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022.		0
1	CD46 targeted ²¹² Pb alpha particle radioimmunotherapy for prostate cancer treatment. 2023 , 42,		0